Yunnan Fuwai Hospital declares successful completion of clinical case of MitralStitch mitral valve repair system. The operation was jointly conducted by the team of Professor Pan Xiangbin and Professor Meng Xu from Beijing Anzhen Hospital under the guidance of Academician Hu Shengshou from Fuwai Hospital. Hangzhou DeJin Medtech Co an affiliate company of DiNovA Medtech developed the MitralStitch mitral valve repair system.
U.S estimates suggests 4.6 million patients grapple with mitral regurgitation. The transcatheter interventional mitral valve technology will bring benefits to patients who cannot be treated surgically, especially those with moderate-to-severe mitral regurgitation and those with high-risk contraindication in surgery.
A small incision width 3-4cm was made between ribs of patient, and MitralStitch mitral valve repair system accessed the left ventricle through the apex of heart. Under the guidance of transesophageal ultrasound, apparatus forceps was operated to clamp prolapsed posterior leaflet of mitral valve and implant artificial chordae tendineae.
The degree of mitral valve regurgitation reduced to mild after operation, and the reflux area decreased from 11.3 cm2 to 1.3 cm2. The ultrasound reexamination before discharge showed that the degree of regurgitation decreased to a very small amount and the patient’s mitral valve function was normal. Symptoms started enhancing thereby routing the cause slowly.
Image Source: Hangzhou Jin Jin Medical Technology Co., Ltd.